Central Bank & Trust Co. Sells 500 Shares of Humana Inc. (NYSE:HUM)

Central Bank & Trust Co. lowered its position in shares of Humana Inc. (NYSE:HUM) by 15.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,799 shares of the insurance provider’s stock after selling 500 shares during the quarter. Central Bank & Trust Co.’s holdings in Humana were worth $710,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HUM. Willner & Heller LLC increased its position in Humana by 28.2% in the fourth quarter. Willner & Heller LLC now owns 2,002 shares of the insurance provider’s stock worth $508,000 after purchasing an additional 440 shares during the period. Liberty One Investment Management LLC bought a new position in shares of Humana in the 4th quarter valued at about $822,000. Clarius Group LLC grew its position in shares of Humana by 7.0% during the 4th quarter. Clarius Group LLC now owns 905 shares of the insurance provider’s stock worth $230,000 after buying an additional 59 shares during the period. Canoe Financial LP bought a new stake in shares of Humana during the fourth quarter worth approximately $62,000. Finally, Merit Financial Group LLC lifted its holdings in Humana by 16.6% in the fourth quarter. Merit Financial Group LLC now owns 1,819 shares of the insurance provider’s stock valued at $461,000 after buying an additional 259 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of HUM opened at $282.63 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $273.81 and its 200 day simple moving average is $307.18. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $415.73. The company has a market cap of $34.03 billion, a price-to-earnings ratio of 25.03, a PEG ratio of 2.02 and a beta of 0.55.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The company had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. On average, research analysts forecast that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.25%. Humana’s payout ratio is 31.36%.

Analyst Upgrades and Downgrades

A number of analysts have commented on HUM shares. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a report on Thursday, October 3rd. Barclays upped their price objective on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Truist Financial boosted their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and cut their price target for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $302.70.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.29% of the stock is currently owned by corporate insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.